A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects
Clinical trial NCT06309043 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06309043
- Sponsor
- Shanghai Henlius Biotech
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-22
- Primary completion
- 2026-06-01
- Enrollment
- 268
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.